| Ytd | 62.44% | |
| 1y | 215.58% |
| Open | 36.00 | Prev Close | 35.78 | Low | 34.56 | High | 36.00 | Mkt Cap | 25.46B |
| Vol | 0.00 | Avg Vol | 6.06M | EPS | -1.05 | P/E | -33.54 | Forward P/E | -21.16 |
| Beta | 1.13 | Short Ratio | 5.83 | Inst. Own | 77.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 33.11 | 200-d Avg | 26.95 | 1yr Est | 41.82 |
ROIV News
Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharm
Roivant Sciences NASDAQ: ROIV said it expects a busy second half of 2026, with a potential launch of
Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.33 per share in line with the Zack
All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' d
Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track f
CS is a highly morbid, chronic, and disfiguring condition with no approved therapies Brepocitinib is
California State Teachers Retirement System boosted its holdings in shares of Roivant Sciences Ltd.
Bank of Nova Scotia cut its stake in Roivant Sciences Ltd. (NASDAQ: ROIV) by 7.9% during the first q
Allspring Global Investments Holdings LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ: RO
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that
BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV)
Roivant Sciences anticipates three commercial launches over the next few years, led by brepocitinib.
HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myosi
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transc
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbust
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
U.S. stocks halt a three-day slide as oil tumbles 5% on revived Iran truce hopes, easing inflation f
US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe'
Roivant Sciences NASDAQ: ROIV executives used the company's fourth-quarter earnings call to highligh
TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Cons
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data s
U.S. stocks were higher, with the Dow Jones index gaining more than 700 points on Friday.
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q
Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keyba
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings f
On Wednesday, 807 companies reached new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
On Wednesday, 160 companies hit new 52-week lows.
On Monday, 671 companies achieved new lows for the year.
Tuesday's session saw 729 companies set new 52-week lows.
On Friday, 368 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Weber (NYSE:WEBR) is projected to report quarterly loss at